Clinical utility of gene-expression profiling for tumor-site origin in patients with metastatic or poorly differentiated cancer: Impact on diagnosis, treatment, and survival

Oncotarget

Volumn 3, Issue 6, 2012, Pages 620-628

  Scott Nystrom, J ^a   Hornberger, John C ^b,c   Varadhachary, Gauri R ^d   Hornberger, Richard J ^c   Gutierrez, Hialy R ^c   David Henner, W ^e   Becker, Shawn H ^e   Amin, Mahul B ^f   Walker, Michael G ^b  

^a TUFTS MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Cedar Associates LLC   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e Pathwork Diagnostics Inc   (United States)

^f CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cancer of unknown primary; Clinical utility; Diagnosis; Genomics; Tissue of origin

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CLINICAL DECISION MAKING; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR LOCALIZATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84866768248     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5):277-300.
2. Greco F and Hainsworth J. Introduction: unknown primary cancer. Semin Oncol. 2009; 36:6-7.
3. Nystrom JS, Weiner JM, Heffelfinger-Juttner J, Irwin LE, Bateman JR and Wolf RM. Metastatic and histologic presentations in unknown primary cancer. Semin Oncol. 1977; 4(1):53-58.
4. Pavlidis N, Briasoulis E and Pentheroudakis G. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21 Suppl 5:v228-231.
5. Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL and JD H. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol. 2008; 26:4442-4448.
6. (2010). National Comprehensive Cancer Network. NCCN Guidelines: Carcinoma of Unknown Primary.
7. Goldstein NS, Hewitt SM, Taylor CR, Yaziji H and DG H. Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol. 2007; 15(2):124-133.
8. Anderson G and Weiss L. Determining tissue of origin for metastatic cancers: Meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol. 2010; 18:3-8.
9. Pillai R, Deeter R, Rigl CT, Nystrom JS, Miller MH, Buturovic L and WD H. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn. 2011; 13(1):48-56.
10. Hainsworth JD, Schnabel CA, Erlander MG, Haines DW, 3rd and Greco FA. A Retrospective Study of Treatment Outcomes in Patients with Carcinoma of Unknown Primary Site and a Colorectal Cancer Molecular Profile. Clinical colorectal cancer. 2011.
11. Dumur CI, Fuller CE, Blevins TL, Schaum JC, Wilkinson DS, Garrett CT and Powers CN. Clinical verification of the performance of the pathwork tissue of origin test: utility and limitations. American journal of clinical pathology. 2011; 136(6):924-933.
12. Lal A, Panos R, Marjanovic M, Walker M, Fuentes E, Kapp DS, Henner WD, Buturovic LJ and Halks-Miller M. A gene expression profile test for the differential diagnosis of ovarian versus endometrial cancers. Oncotarget. 2012; 3(2):212-223.
13. Berg A, Armstrong K, Botkin J, Calonge N, Haddow J, Hayes M, Kaye C, Phillips K, Piper M, Richards C, Scott J, Strickland O and Teutsch S. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med. 2009; 11(1):15-20.
14. Sun F, Bruening W, Uhl S, Ballard R, Tipton K and Schoelles K. (2010). Quality, regulation, and clinical utility of laboratory-developed molecular tests. Agency for Healthcare Research and Quality (AHRQ)).
15. M L, M H-M, WD H and JS N. Potential clinical utility of gene expression profiling in identifying tumors of uncertain origin. Personalized Medicine. in press.
16. Altman E and Cadman E. An analysis of 1539 patients with cancer of unknown primary site. Cancer. 1986; 57(1):120-124.
17. Markman M. Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at The Johns Hopkins Hospital from 1965-1979. Med Pediatr Oncol. 1982; 10(6):569-574.
18. van de Wouw AJ, Janssen-Heijnen ML, Coebergh JW and Hillen HF. Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in Southeast Netherlands, 1984-1992. Eur J Cancer. 2002; 38(3):409-413.
19. Botkin J, Teutsch S, Kaye C, Hayes M, Haddow J, Bradley L, Szegda K and Dotson D. Outcomes of interest in evidence-based evaluations of genetic tests. Genet Med. 2010; 12(4):228-235.
20. Teutsch S, Bradley L, Palomaki G, Haddow J, Piper M, Calonge N, Dotson D, Douglas M and Berg A. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med. 2009; 11(1):3-14.
21. Witkiewicz AK, Kline J, Queenan M, Brody JR, Tsirigos A, Bilal E, Pavlides S, Ertel A, Sotgia F and Lisanti MP. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle. 2011; 10(11):1794-1809.
22. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE and Knudsen ES. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle. 2010; 9(20):4153-4163.
23. Greco FA, Gray J, Burris HA, 3rd, Erland JB, Morrissey LH and Hainsworth JD. Taxane-based chemotherapy for patients with carcinoma of unknown primary site. Cancer J. 2001; 7(3):203-212.
24. Hainsworth JD, Spigel DR, Farley C, Thompson DS, Shipley DL and Greco FA. Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol. 2007; 25(13):1747-1752.
25. Huebner G, Link H, Kohne CH, Stahl M, Kretzschmar A, Steinbach S, Folprecht G, Bernhard H, Al-Batran SE, Schoffski P, Burkart C, Kullmann F, Otremba B, Menges M, Hoffmann M, Kaiser U, et al. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adenoor undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer. 2009; 100(1):44-49.
26. Fleiss JL, Levin B and Paik MC. (2003). Statistical Methods for Rates and Proportions. (New York: John Wiley & Sons).
27. Newcombe R. Two-sided confidence intervals for the single proportion: comparison of seven methods. Statistics in Medicine. 1998; 17(8):857-872.
28. (2005). Stata Statistical Software. Release 9. (College Station, TX: StataCorp LP).
29. (2010). National Comprehensive Cancer Network. NCCN Guidelines: Carcinoma of Unknown Primary.
30. (2011). UpToDate. In: Basow D, ed. (Waltham, MA)